Glencore


Testing times are aggravating and lasting (a bit) longer

04/10/19 -"Apart from a gruesome H1 19, the commodity market’s pain has sustained so far. Even though some efficiency/cost improvements should materialise as we approach the end of the year, a meaningful ..."

Pages
64
Language
English
Published on
04/10/19
You may also be interested by these reports :
07/08/20
Q2 results were rather modest in the context of the pandemic and still high imports to Europe In particular, more than half of the profits stem from ...

07/08/20
Although acute market volatility translated into an H1 bonanza for trading, Glencore’s COVID-19 vulnerability came to the fore as industrial reported ...

06/08/20
Q2 was weak as expected due to oil prices and the pandemic The outlook for Q3 is very cautious In particular, America remains a concern given the ...

05/08/20
We have fine-tuned our forecasts in the light of H1 20 results. In particular, we have integrated a somewhat lower EBITDA margin and the weight of ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO